Endologix Inc. (ELGX) gapped open sharply lower Thursday morning and has continued to fall in early trade. The stock is now down 2.35 at $4.38 on above average volume. Endologix has dropped below support and has set a new low for the year.
Endologix announced Wednesday that, after a meeting with the FDA, it will conduct a confirmatory clinical study of its Nellix EVAS System. The company now estimates that PMA approval will occur in 2020.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.